Skip to main content
. 2020 Jun 2;11(22):2120–2136. doi: 10.18632/oncotarget.27596

Figure 3. Functionalized nanoparticle platform with various targeting ligand agents for active PS delivery in PDT applications, with PEG to improve biocompatibility and an imaging fluorescent probe to monitor PS specific tumour cellular uptake.

Figure 3